BioSpecifics Technologies Corp. (NASDAQ:BSTC) Director Toby Wegman sold 10,000 shares of the business’s stock in a transaction on Tuesday, November 29th. The stock was sold at an average price of $48.08, for a total value of $480,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) traded up 5.06% during mid-day trading on Tuesday, reaching $49.85. The company’s stock had a trading volume of 82,988 shares. The stock has a 50-day moving average price of $45.99 and a 200-day moving average price of $41.13. The company has a market capitalization of $356.28 million, a price-to-earnings ratio of 32.80 and a beta of 1.35. BioSpecifics Technologies Corp. has a one year low of $30.70 and a one year high of $51.90.

Insider Buying and Selling by Quarter for BioSpecifics Technologies Corp. (NASDAQ:BSTC)

COPYRIGHT VIOLATION WARNING: “BioSpecifics Technologies Corp. (BSTC) Director Sells $480,800.00 in Stock” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2016/11/29/biospecifics-technologies-corp-bstc-director-sells-480800-00-in-stock.html.

A number of analysts recently commented on BSTC shares. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of BioSpecifics Technologies Corp. in a research report on Thursday, October 6th. Rodman & Renshaw reiterated a “buy” rating and set a $60.00 price objective on shares of BioSpecifics Technologies Corp. in a research report on Wednesday, August 10th. Finally, Zacks Investment Research upgraded BioSpecifics Technologies Corp. from a “hold” rating to a “strong-buy” rating and set a $45.00 price objective for the company in a research report on Thursday, August 11th.

Hedge funds have recently made changes to their positions in the stock. Morgan Stanley boosted its stake in shares of BioSpecifics Technologies Corp. by 977.8% in the third quarter. Morgan Stanley now owns 2,188 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 1,985 shares during the period. US Bancorp DE boosted its stake in shares of BioSpecifics Technologies Corp. by 21.0% in the second quarter. US Bancorp DE now owns 3,025 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 525 shares during the period. American International Group Inc. boosted its stake in shares of BioSpecifics Technologies Corp. by 4.2% in the second quarter. American International Group Inc. now owns 3,110 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 126 shares during the period. Nationwide Fund Advisors boosted its stake in shares of BioSpecifics Technologies Corp. by 6.5% in the second quarter. Nationwide Fund Advisors now owns 3,563 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 217 shares during the period. Finally, Bank of Montreal Can bought a new stake in shares of BioSpecifics Technologies Corp. during the second quarter valued at about $152,000. 53.71% of the stock is currently owned by institutional investors and hedge funds.

BioSpecifics Technologies Corp. Company Profile

BioSpecifics Technologies Corp. (BioSpecifics) is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. The Company has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development.

5 Day Chart for NASDAQ:BSTC

Receive News & Stock Ratings for BioSpecifics Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp. and related stocks with our FREE daily email newsletter.